Matthew Galsky, MD
img_Matthew Galsky
PROFESSOR | Medicine, Hematology and Medical Oncology
PROFESSOR | Urology
Are you a patient?
Specialties
Cancer (Oncology)

MD, Tufts University

Residency, Internal Medicine, Beth Israel Deaconess Medical Center

Fellowship, Medical Oncology, Memorial Sloan-Kettering Cancer Center

Certifications

American Board of Internal Medicine

2003

American Society of Clinical Oncology Merit Award

1998

Medical Calss of 1928 Award (Tufts School of Medicine, Excellence in Anatomy)

1998

Leon Levinson Prize (Tufts School of Medicine, Excellence in Physiology)

1997

Alpha Omega Alpha Honor Society

Publications

Selected Publications

Corrigendum to “Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score” [Eur. Urol. 83(5) (2024) 432–440] (European Urology (2023) 83(5) (432–440), (S030228382300026X), (10.1016/j.eururo.2023.01.016)). Matthew D. Galsky, Dean F. Bajorin, Johannes Alfred Witjes, Jürgen E. Gschwend, Yoshihiko Tomita, Federico Nasroulah, Jun Li, Sandra Collette, Begoña P. Valderrama, Marc Oliver Grimm, Leonard Appleman, Gwenaelle Gravis, Andrea Necchi, Dingwei Ye, Frank Stenner, Megan Wind-Rotolo, Joshua Zhang, Keziban Ünsal-Kaçmaz. European Urology

Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer. Matthew D. Galsky, Xiangnan Guan, Deepali Rishipathak, Aaron S. Rapaport, Hesham M. Shehata, Romain Banchereau, Kobe Yuen, Eugene Varfolomeev, Ruozhen Hu, Chia Jung Han, Haocheng Li, Yuxin Liang, Domagoj Vucic, Li Wang, Jun Zhu, Haocheng Yu, Rebecca H. Herbst, Emma Hajaj, Evgeny Kiner, Aristotelis Bamias, Maria De Santis, Ian D. Davis, José Ángel Arranz, Eiji Kikuchi, Sandrine Bernhard, Patrick Williams, Chooi Lee, Ira Mellman, Shomyseh Sanjabi, Robert Johnston, Peter C. Black, Enrique Grande, Sanjeev Mariathasan. Cell Reports Medicine

Toward standardization in bladder cancer clinical trials: Guidance from the SITC-IBCG expert panel. Amanda A. Myers, Ashish M. Kamat, Angela Kilbert, Matthew D. Galsky. Journal for ImmunoTherapy of Cancer

View All Publications

Immune Checkpoint Blockade: A New Era in Cancer Treatment

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Galsky during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • Bristol-Myers Squibb
  • Pfizer Inc.
  • Asieris Pharmaceutical Technologies Co., Ltd
  • NuMab
  • Bicycle
  • Rappta Therapeutics
  • Curis Inc.
  • FUJIFILM Medical Systems U.S.A., Inc.
  • Genentech, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Alligator
  • AbbVie, Inc.
  • Silverback
  • AstraZeneca
  • Seattle Genetics
  • EMD Serono, Inc
  • Gilead Sciences

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.